Published in J Virol on March 01, 2005
Current advances and future challenges in Adenoviral vector biology and targeting. Curr Gene Ther (2007) 1.94
Hexon modification to improve the activity of oncolytic adenovirus vectors against neoplastic and stromal cells in pancreatic cancer. PLoS One (2015) 1.43
Tropism-modification strategies for targeted gene delivery using adenoviral vectors. Viruses (2010) 1.17
Epitopes expressed in different adenovirus capsid proteins induce different levels of epitope-specific immunity. J Virol (2006) 1.14
Characterization of a permissive epitope insertion site in adenovirus hexon. J Virol (2006) 1.10
Strategies to overcome host immunity to adenovirus vectors in vaccine development. Expert Rev Vaccines (2009) 1.08
HIV antigen incorporation within adenovirus hexon hypervariable 2 for a novel HIV vaccine approach. PLoS One (2010) 1.07
Optimization of capsid-incorporated antigens for a novel adenovirus vaccine approach. Virol J (2008) 1.03
Adenoviral vector-based strategies for cancer therapy. Curr Drug ther (2009) 1.02
Substitution of adenovirus serotype 3 hexon onto a serotype 5 oncolytic adenovirus reduces factor X binding, decreases liver tropism, and improves antitumor efficacy. Mol Cancer Ther (2010) 1.02
Adenovirus receptors and their implications in gene delivery. Virus Res (2009) 0.98
Capsid-incorporation of antigens into adenovirus capsid proteins for a vaccine approach. Mol Pharm (2010) 0.97
Chapter two--Adenovirus strategies for tissue-specific targeting. Adv Cancer Res (2012) 0.90
Protection against enterovirus 71 with neutralizing epitope incorporation within adenovirus type 3 hexon. PLoS One (2012) 0.90
Using multivalent adenoviral vectors for HIV vaccination. PLoS One (2013) 0.87
The evolution of adenoviral vectors through genetic and chemical surface modifications. Viruses (2014) 0.86
Prospects for oral replicating adenovirus-vectored vaccines. Vaccine (2013) 0.86
Current progress in the development of a prophylactic vaccine for HIV-1. Drug Des Devel Ther (2010) 0.85
Adenovirus with hexon Tat-protein transduction domain modification exhibits increased therapeutic effect in experimental neuroblastoma and neuroendocrine tumors. J Virol (2011) 0.84
Immunization with Hexon modified adenoviral vectors integrated with gp83 epitope provides protection against Trypanosoma cruzi infection. PLoS Negl Trop Dis (2014) 0.84
Derivation of a triple mosaic adenovirus for cancer gene therapy. PLoS One (2009) 0.81
Targeting of adenovirus serotype 5 pseudotyped with short fiber from serotype 41 to c-erbB2-positive cells using bispecific single-chain diabody. J Mol Biol (2009) 0.80
A recombinant adenovirus-based vector elicits a specific humoral immune response against the V3 loop of HIV-1 gp120 in mice through the "Antigen Capsid-Incorporation" strategy. Virol J (2014) 0.80
Adenoviral vectors elicit humoral immunity against variable loop 2 of clade C HIV-1 gp120 via "Antigen Capsid-Incorporation" strategy. Virology (2015) 0.79
CryoEM visualization of an adenovirus capsid-incorporated HIV antigen. PLoS One (2012) 0.77
A Plasmodium Promiscuous T Cell Epitope Delivered within the Ad5 Hexon Protein Enhances the Protective Efficacy of a Protein Based Malaria Vaccine. PLoS One (2016) 0.76
Construction of a pIX-modified Adenovirus Vector Able to Effectively Bind to Nanoantibodies for Targeting. Acta Naturae (2014) 0.76
Epitope Capsid-Incorporation: New Effective Approach for Vaccine Development for Chagas Disease. Pathog Immun (2016) 0.75
Exploration of New Sites in Adenovirus Hexon for Foreign Peptides Insertion. Open Virol J (2015) 0.75
Utilizing the antigen capsid-incorporation strategy for the development of adenovirus serotype 5-vectored vaccine approaches. J Vis Exp (2015) 0.75
Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science (1997) 14.41
Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell (1993) 13.21
Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol (1995) 5.67
Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. Proc Natl Acad Sci U S A (1995) 3.90
An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol (1998) 3.32
Mutations that alter an Arg-Gly-Asp (RGD) sequence in the adenovirus type 2 penton base protein abolish its cell-rounding activity and delay virus reproduction in flat cells. J Virol (1993) 3.29
Structural proteins of adenoviruses. X. Isolation and topography of low molecular weight antigens from the virion of adenovirus type 2. Virology (1973) 3.26
Analysis of 15 adenovirus hexon proteins reveals the location and structure of seven hypervariable regions containing serotype-specific residues. J Virol (1996) 3.01
Adenovirus targeted to heparan-containing receptors increases its gene delivery efficiency to multiple cell types. Nat Biotechnol (1996) 2.69
Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins. J Virol (1997) 2.64
Neutralization of adenoviruses: kinetics, stoichiometry, and mechanisms. J Virol (1988) 2.61
Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors. J Virol (2002) 2.55
Adenovirus type 5 and 7 capsid chimera: fiber replacement alters receptor tropism without affecting primary immune neutralization epitopes. J Virol (1996) 2.46
Three-dimensional structure of the adenovirus major coat protein hexon. Science (1986) 2.41
Type-specific epitope locations revealed by X-ray crystallographic study of adenovirus type 5 hexon. Mol Ther (2000) 2.40
Cell-binding domain of adenovirus serotype 2 fiber. J Virol (1994) 2.16
PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo. Hum Gene Ther (1999) 2.11
Structural and phylogenetic analysis of adenovirus hexons by use of high-resolution x-ray crystallographic, molecular modeling, and sequence-based methods. J Virol (2003) 2.10
Role of alpha(v) integrins in adenovirus cell entry and gene delivery. Microbiol Mol Biol Rev (1999) 1.90
Immune response to recombinant capsid proteins of adenovirus in humans: antifiber and anti-penton base antibodies have a synergistic effect on neutralizing activity. J Virol (1998) 1.75
Variability of human systemic humoral immune responses to adenovirus gene transfer vectors administered to different organs. J Virol (1999) 1.61
Immunology of gene therapy with adenoviral vectors in mouse skeletal muscle. Hum Mol Genet (1996) 1.60
The refined crystal structure of hexon, the major coat protein of adenovirus type 2, at 2.9 A resolution. J Mol Biol (1994) 1.57
Construction and characterization of hexon-chimeric adenoviruses: specification of adenovirus serotype. J Virol (1998) 1.55
High-efficiency gene transfer mediated by adenovirus coupled to DNA-polylysine complexes. Hum Gene Ther (1992) 1.45
A system for the propagation of adenoviral vectors with genetically modified receptor specificities. Nat Biotechnol (1999) 1.39
Hexon gene switch strategy for the generation of chimeric recombinant adenovirus. Hum Gene Ther (2002) 1.37
RGD inclusion in the hexon monomer provides adenovirus type 5-based vectors with a fiber knob-independent pathway for infection. J Virol (1999) 1.37
Targeted adenoviral vectors. Biochim Biophys Acta (2002) 1.36
Construction and characterization of adenovirus serotype 5 packaged by serotype 3 hexon. J Virol (2002) 1.35
Engineering of adenovirus vectors containing heterologous peptide sequences in the C terminus of capsid protein IX. J Virol (2002) 1.35
Adenovirus hexon protein is a potent adjuvant for activation of a cellular immune response. J Virol (2002) 1.34
The therapeutic efficacy of adenoviral vectors for cancer gene therapy is limited by a low level of primary adenovirus receptors on tumour cells. Eur J Cancer (2002) 1.29
Adenoviral gene therapy. Oncologist (2002) 1.26
Circumvention of immunity to the adenovirus major coat protein hexon. J Virol (1998) 1.26
Transient immunosuppression permits successful repetitive intravenous administration of an adenovirus vector. Gene Ther (1996) 1.25
Expression of a foreign epitope on the surface of the adenovirus hexon. J Gen Virol (1994) 1.25
Fluorescently labeled adenovirus with pIX-EGFP for vector detection. Mol Imaging (2004) 1.18
Molecular determinants of adenovirus serotype 5 fibre binding to its cellular receptor CAR. J Gen Virol (1999) 1.16
Double modification of adenovirus fiber with RGD and polylysine motifs improves coxsackievirus-adenovirus receptor-independent gene transfer efficiency. Hum Gene Ther (2002) 1.16
The structure of the adenovirus capsid. III. Hexon packing determined from electron micrographs of capsid fragments. J Mol Biol (1987) 1.06
Generation of fiber-modified adenovirus vectors containing heterologous peptides in both the HI loop and C terminus of the fiber knob. J Gene Med (2003) 1.04
Virus assembly. Curr Top Microbiol Immunol (1995) 1.01
Improvements in gene therapy: averting the immune response to adenoviral vectors. BioDrugs (2002) 0.99
Single oral immunization with replication deficient recombinant adenovirus elicits long-lived transgene-specific cellular and humoral immune responses. Virology (2002) 0.98
Adenovirus structure by X-ray crystallography and electron microscopy. Curr Top Microbiol Immunol (1995) 0.94
Poly-L-lysine improves gene transfer with adenovirus formulated in PLGA microspheres. Gene Ther (1999) 0.91
Enhancement of adenoviral transduction with polycationic liposomes in vivo. Cancer Gene Ther (2000) 0.86
Adenoviral vectors--new insights. Trends Microbiol (2000) 0.85
Fiber shaft extension in combination with HI loop ligands augments infectivity for CAR-negative tumor targets but does not enhance hepatotropism in vivo. Gene Ther (2002) 0.84
Mechanism of adenovirus improvement of cationic liposome-mediated gene transfer. Biochim Biophys Acta (1997) 0.82
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med (2003) 7.35
Corneal avascularity is due to soluble VEGF receptor-1. Nature (2006) 4.77
Engineering targeted viral vectors for gene therapy. Nat Rev Genet (2007) 3.69
Radiation-induced cell signaling: inside-out and outside-in. Mol Cancer Ther (2007) 2.56
Mechanism of autophagy to apoptosis switch triggered in prostate cancer cells by antitumor cytokine melanoma differentiation-associated gene 7/interleukin-24. Cancer Res (2010) 2.13
MDA-7 regulates cell growth and radiosensitivity in vitro of primary (non-established) human glioma cells. Cancer Biol Ther (2004) 1.90
Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses. Mol Cancer Ther (2006) 1.88
Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. J Natl Cancer Inst (2003) 1.86
A canine conditionally replicating adenovirus for evaluating oncolytic virotherapy in a syngeneic animal model. Mol Ther (2003) 1.86
Current issues and future directions of oncolytic adenoviruses. Mol Ther (2009) 1.80
Adenoviral gene therapy for renal cancer requires retargeting to alternative cellular receptors. Cancer Res (2002) 1.74
Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells. Clin Cancer Res (2002) 1.74
FCRL2 expression predicts IGHV mutation status and clinical progression in chronic lymphocytic leukemia. Blood (2008) 1.67
Enhanced adenovirus infection of melanoma cells by fiber-modification: incorporation of RGD peptide or Ad5/3 chimerism. Cancer Biol Ther (2003) 1.66
Self-assembling nanoclusters in living systems: application for integrated photothermal nanodiagnostics and nanotherapy. Nanomedicine (2005) 1.66
mda-7/IL-24, a novel cancer selective apoptosis inducing cytokine gene: from the laboratory into the clinic. Cancer Biol Ther (2003) 1.63
In vivo molecular chemotherapy and noninvasive imaging with an infectivity-enhanced adenovirus. J Natl Cancer Inst (2002) 1.61
Covalently linked Au nanoparticles to a viral vector: potential for combined photothermal and gene cancer therapy. Nano Lett (2006) 1.61
mda-7/IL-24: multifunctional cancer-specific apoptosis-inducing cytokine. Pharmacol Ther (2006) 1.56
Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation. Clin Cancer Res (2008) 1.55
OSU-03012 stimulates PKR-like endoplasmic reticulum-dependent increases in 70-kDa heat shock protein expression, attenuating its lethal actions in transformed cells. Mol Pharmacol (2008) 1.52
Survivin-driven and fiber-modified oncolytic adenovirus exhibits potent antitumor activity in established intracranial glioma. Hum Gene Ther (2007) 1.48
Caspase-, cathepsin-, and PERK-dependent regulation of MDA-7/IL-24-induced cell killing in primary human glioma cells. Mol Cancer Ther (2008) 1.48
Development of a generic adenovirus delivery system based on structure-guided design of bispecific trimeric DARPin adapters. Proc Natl Acad Sci U S A (2013) 1.46
A novel ex vivo model system for evaluation of conditionally replicative adenoviruses therapeutic efficacy and toxicity. Clin Cancer Res (2004) 1.44
Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus. Mol Ther (2003) 1.43
Oncolytic adenoviruses - selective retargeting to tumor cells. Oncogene (2005) 1.43
Mesenchymal stem cells as a vehicle for targeted delivery of CRAds to lung metastases of breast carcinoma. Breast Cancer Res Treat (2007) 1.41
Targeting Mcl-1 for the therapy of cancer. Expert Opin Investig Drugs (2011) 1.39
Construction and characterization of adenovirus serotype 5 packaged by serotype 3 hexon. J Virol (2002) 1.35
Engineering of adenovirus vectors containing heterologous peptide sequences in the C terminus of capsid protein IX. J Virol (2002) 1.35
mda-7/IL-24, novel anticancer cytokine: focus on bystander antitumor, radiosensitization and antiangiogenic properties and overview of the phase I clinical experience (Review). Int J Oncol (2007) 1.34
Modulation of adenovirus vector tropism via incorporation of polypeptide ligands into the fiber protein. J Virol (2002) 1.33
Apogossypol derivative BI-97C1 (Sabutoclax) targeting Mcl-1 sensitizes prostate cancer cells to mda-7/IL-24-mediated toxicity. Proc Natl Acad Sci U S A (2011) 1.31
Eradication of therapy-resistant human prostate tumors using a cancer terminator virus. Cancer Res (2007) 1.31
Potential of the conditionally replicative adenovirus Ad5-Delta24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy. Cancer Res (2002) 1.30
mda-7/IL-24: a unique member of the IL-10 gene family promoting cancer-targeted toxicity. Cytokine Growth Factor Rev (2010) 1.30
Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses. Mol Ther (2002) 1.28
Infectivity enhanced, cyclooxygenase-2 promoter-based conditionally replicative adenovirus for pancreatic cancer. Gastroenterology (2003) 1.28
Adenovirus serotype 3 utilizes CD80 (B7.1) and CD86 (B7.2) as cellular attachment receptors. Virology (2004) 1.27
Historical perspective and recent insights into our understanding of the molecular and biochemical basis of the antitumor properties of mda-7/IL-24. Cancer Biol Ther (2009) 1.25
PERK-dependent regulation of ceramide synthase 6 and thioredoxin play a key role in mda-7/IL-24-induced killing of primary human glioblastoma multiforme cells. Cancer Res (2010) 1.23
Structure and uncoating of immature adenovirus. J Mol Biol (2009) 1.23
A phase I study of a tropism-modified conditionally replicative adenovirus for recurrent malignant gynecologic diseases. Clin Cancer Res (2010) 1.21
The human survivin promoter: a novel transcriptional targeting strategy for treatment of glioma. J Neurosurg (2006) 1.21
Interleukin-6 induces both cell growth and VEGF production in malignant mesotheliomas. Int J Cancer (2006) 1.19
Fluorescently labeled adenovirus with pIX-EGFP for vector detection. Mol Imaging (2004) 1.18
Current developments in adenovirus-based cancer gene therapy. Future Oncol (2006) 1.18
MDA-7/IL-24 plus radiation enhance survival in animals with intracranial primary human GBM tumors. Cancer Biol Ther (2008) 1.18
Mechanism by which Mcl-1 regulates cancer-specific apoptosis triggered by mda-7/IL-24, an IL-10-related cytokine. Cancer Res (2010) 1.18
Genetically targeted adenovirus vector directed to CD40-expressing cells. J Virol (2003) 1.18
The presence of the adenovirus E3 region improves the oncolytic potency of conditionally replicative adenoviruses. Clin Cancer Res (2002) 1.17
Molecular imaging of active mutant L858R EGF receptor (EGFR) kinase-expressing nonsmall cell lung carcinomas using PET/CT. Proc Natl Acad Sci U S A (2011) 1.16
Double modification of adenovirus fiber with RGD and polylysine motifs improves coxsackievirus-adenovirus receptor-independent gene transfer efficiency. Hum Gene Ther (2002) 1.16
Delta-24 increases the expression and activity of topoisomerase I and enhances the antiglioma effect of irinotecan. Clin Cancer Res (2006) 1.15
Treatment of ovarian cancer with a tropism modified oncolytic adenovirus. Cancer Res (2002) 1.15
Eradication of therapy-resistant human prostate tumors using an ultrasound-guided site-specific cancer terminator virus delivery approach. Mol Ther (2009) 1.14
Promotion of incisional wound repair by human mesenchymal stem cell transplantation. Exp Dermatol (2008) 1.14
Novel oncolytic adenoviruses targeted to melanoma: specific viral replication and cytolysis by expression of E1A mutants from the tyrosinase enhancer/promoter. Cancer Res (2002) 1.14
Intravenous delivery of adenovirus-mediated soluble FLT-1 results in liver toxicity. Clin Cancer Res (2003) 1.14
Safety and immunogenicity of a DNA vaccine encoding carcinoembryonic antigen and hepatitis B surface antigen in colorectal carcinoma patients. Clin Cancer Res (2002) 1.13
Genetic incorporation of a herpes simplex virus type 1 thymidine kinase and firefly luciferase fusion into the adenovirus protein IX for functional display on the virion. Mol Imaging (2006) 1.13
Contrasting effects of human, canine, and hybrid adenovirus vectors on the phenotypical and functional maturation of human dendritic cells: implications for clinical efficacy. J Virol (2007) 1.13
Three-dimensional structure of canine adenovirus serotype 2 capsid. J Virol (2008) 1.13
Triple-targeted oncolytic adenoviruses featuring the cox2 promoter, E1A transcomplementation, and serotype chimerism for enhanced selectivity for ovarian cancer cells. Mol Ther (2006) 1.12
Synergistic combinations of signaling pathway inhibitors: mechanisms for improved cancer therapy. Drug Resist Updat (2009) 1.12
Transcriptional targeting of tumors with a novel tumor-specific survivin promoter. Cancer Gene Ther (2004) 1.12
Melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24): novel gene therapeutic for metastatic melanoma. Toxicol Appl Pharmacol (2006) 1.12
Regulation of GST-MDA-7 toxicity in human glioblastoma cells by ERBB1, ERK1/2, PI3K, and JNK1-3 pathway signaling. Mol Cancer Ther (2008) 1.11
Scavenger receptor A: a new route for adenovirus 5. Mol Pharm (2009) 1.10
A phase I clinical trial of Ad5/3-Δ24, a novel serotype-chimeric, infectivity-enhanced, conditionally-replicative adenovirus (CRAd), in patients with recurrent ovarian cancer. Gynecol Oncol (2013) 1.10
Mitogen-activated protein kinase kinase 1/2 inhibitors and 17-allylamino-17-demethoxygeldanamycin synergize to kill human gastrointestinal tumor cells in vitro via suppression of c-FLIP-s levels and activation of CD95. Mol Cancer Ther (2008) 1.10
A novel class of vascular endothelial growth factor-responsive genes that require forkhead activity for expression. J Biol Chem (2006) 1.10
Dynamic monitoring of oncolytic adenovirus in vivo by genetic capsid labeling. J Natl Cancer Inst (2006) 1.10
Transductional targeting of adenoviral cancer gene therapy. Curr Gene Ther (2004) 1.10
Members of adenovirus species B utilize CD80 and CD86 as cellular attachment receptors. Virus Res (2006) 1.09